BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 17089053)

  • 1. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary.
    Takano M; Kikuchi Y; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Sugiyama T
    Oncol Rep; 2006 Dec; 16(6):1301-6. PubMed ID: 17089053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
    Takano M; Sugiyama T; Yaegashi N; Suzuki M; Tsuda H; Sagae S; Udagawa Y; Kuzuya K; Kigawa J; Takeuchi S; Tsuda H; Moriya T; Kikuchi Y
    Int J Clin Oncol; 2007 Aug; 12(4):256-60. PubMed ID: 17701003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term survival in patients with clear cell adenocarcinoma of ovary treated with irinotecan hydrochloride plus cisplatin therapy as first-line chemotherapy.
    Kunito S; Takakura S; Nagata C; Saito M; Yanaihara N; Yamada K; Okamoto A; Sasaki H; Ochiai K; Tanaka T
    J Obstet Gynaecol Res; 2012 Dec; 38(12):1367-75. PubMed ID: 22639843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan hydrochloride (CPT-11) and mitomycin C as the first line chemotherapy for ovarian clear cell adenocarcinoma.
    Nishino K; Aoki Y; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
    Gynecol Oncol; 2005 Jun; 97(3):893-7. PubMed ID: 15894369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
    Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
    Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial.
    Sugiyama T; Okamoto A; Enomoto T; Hamano T; Aotani E; Terao Y; Suzuki N; Mikami M; Yaegashi N; Kato K; Yoshikawa H; Yokoyama Y; Tanabe H; Nishino K; Nomura H; Kim JW; Kim BG; Pignata S; Alexandre J; Green J; Isonishi S; Terauchi F; Fujiwara K; Aoki D
    J Clin Oncol; 2016 Aug; 34(24):2881-7. PubMed ID: 27400948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study.
    Takano M; Sugiyama T; Yaegashi N; Sagae S; Kuzuya K; Udagawa Y; Tsuda H; Suzuki M; Kigawa J; Goto T; Tsuda H; Moriya T; Kikuchi Y
    Int J Gynecol Cancer; 2010 Dec; 20(9):1506-10. PubMed ID: 21119366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.
    Kajiyama H; Shibata K; Suzuki S; Ino K; Kawai M; Nagasaka T; Nawa A; Kikkawa F
    Gynecol Obstet Invest; 2011; 72(4):252-6. PubMed ID: 22041903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
    Takakura S; Takano M; Takahashi F; Saito T; Aoki D; Inaba N; Noda K; Sugiyama T; Ochiai K;
    Int J Gynecol Cancer; 2010 Feb; 20(2):240-7. PubMed ID: 20169667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma.
    Takakura S; Saito M; Ueda K; Motegi M; Takao M; Yamada K; Okamoto A; Niimi S; Sasaki H; Tanaka T; Ochiai K
    Int Surg; 2007; 92(4):202-8. PubMed ID: 18050828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic analysis of 88 patients with ovarian clear cell carcinoma].
    Ma SK; Zhang HT; Wu LY; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):784-8. PubMed ID: 18396695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience.
    Chun KC; Kim JJ; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
    Gynecol Obstet Invest; 2011; 72(3):208-14. PubMed ID: 21968161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.
    Suzuki K; Takakura S; Saito M; Morikawa A; Suzuki J; Takahashi K; Nagata C; Yanaihara N; Tanabe H; Okamoto A
    Int J Gynecol Cancer; 2014 Sep; 24(7):1181-9. PubMed ID: 25010038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
    Chang SJ; Bristow RE; Ryu HS
    Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory study of effective chemotherapy to clear cell carcinoma of the ovary.
    Kita T; Kikuchi Y; Kudoh K; Takano M; Goto T; Hirata J; Tode T; Nagata I
    Oncol Rep; 2000; 7(2):327-31. PubMed ID: 10671681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy.
    Bamias A; Psaltopoulou T; Sotiropoulou M; Haidopoulos D; Lianos E; Bournakis E; Papadimitriou C; Rodolakis A; Vlahos G; Dimopoulos MA
    Cancer; 2010 Mar; 116(6):1462-8. PubMed ID: 20108307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Successful optimal debulking surgery following chemotherapy combined with irinotecan hydrochloride and cisplatin for advanced clear cell carcinoma of the ovary].
    Hirakawa H; Futagami M; Yokoyama Y; Hakamada K; Mizunuma H
    Gan To Kagaku Ryoho; 2011 May; 38(5):857-60. PubMed ID: 21566454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.